| Dr John Joe Pomann Iii, MD | |
|
16510 19 Mile Rd, Clinton Twp, MI 48038-1106 | |
| (586) 263-7200 | |
| Not Available |
| Full Name | Dr John Joe Pomann Iii |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 22 Years |
| Location | 16510 19 Mile Rd, Clinton Twp, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114933843 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 4301080312 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Henry Ford Macomb Hospital | Clinton township, MI | Hospital |
| Beaumont Hospital, Troy | Troy, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Midwest Center For Dermatology And Pathology Pllc | 0446330492 | 43 |
News Archive
Inhibitex, Inc., announced today that it has completed enrollment in a Phase II clinical trial of FV-100 in shingles (herpes zoster) patients. The objectives of the trial are to further evaluate the safety of FV-100 and its potential therapeutic benefit in reducing the severity and duration of shingles-associated pain, the incidence of post herpetic neuralgia (PHN), and the time to heal shingles-related lesions.
Beneficiaries are encouraged to take a close look at their options during their upcoming enrollment period, which is separate from the sign-up in the health law's marketplaces.
Displays of altruism or selflessness towards others can be sexually attractive in a mate. This is one of the findings of a study carried out by biologists and a psychologist at The University of Nottingham.
Many first responders working at Ground Zero following the 9/11 tragedy were exposed to cement dust, smoke, glass fibers, and heavy metals. Exposure to high levels of such particulate matter caused significant damage to first responders' kidneys, according to research presented at ASN Kidney Week 2013 November 9 at the Georgia World Congress Center in Atlanta, GA.
Gilead Sciences, Inc. announced today its results of operations for the fourth quarter and full year 2012.
› Verified 3 days ago
| Entity Name | Midwest Center For Dermatology & Pathology Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003095084 PECOS PAC ID: 0446330492 Enrollment ID: O20080103000679 |
News Archive
Inhibitex, Inc., announced today that it has completed enrollment in a Phase II clinical trial of FV-100 in shingles (herpes zoster) patients. The objectives of the trial are to further evaluate the safety of FV-100 and its potential therapeutic benefit in reducing the severity and duration of shingles-associated pain, the incidence of post herpetic neuralgia (PHN), and the time to heal shingles-related lesions.
Beneficiaries are encouraged to take a close look at their options during their upcoming enrollment period, which is separate from the sign-up in the health law's marketplaces.
Displays of altruism or selflessness towards others can be sexually attractive in a mate. This is one of the findings of a study carried out by biologists and a psychologist at The University of Nottingham.
Many first responders working at Ground Zero following the 9/11 tragedy were exposed to cement dust, smoke, glass fibers, and heavy metals. Exposure to high levels of such particulate matter caused significant damage to first responders' kidneys, according to research presented at ASN Kidney Week 2013 November 9 at the Georgia World Congress Center in Atlanta, GA.
Gilead Sciences, Inc. announced today its results of operations for the fourth quarter and full year 2012.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John Joe Pomann Iii, MD 2710 Forest View Ct, Rochester Hills, MI 48307-5905 Ph: (248) 270-4201 | Dr John Joe Pomann Iii, MD 16510 19 Mile Rd, Clinton Twp, MI 48038-1106 Ph: (586) 263-7200 |
News Archive
Inhibitex, Inc., announced today that it has completed enrollment in a Phase II clinical trial of FV-100 in shingles (herpes zoster) patients. The objectives of the trial are to further evaluate the safety of FV-100 and its potential therapeutic benefit in reducing the severity and duration of shingles-associated pain, the incidence of post herpetic neuralgia (PHN), and the time to heal shingles-related lesions.
Beneficiaries are encouraged to take a close look at their options during their upcoming enrollment period, which is separate from the sign-up in the health law's marketplaces.
Displays of altruism or selflessness towards others can be sexually attractive in a mate. This is one of the findings of a study carried out by biologists and a psychologist at The University of Nottingham.
Many first responders working at Ground Zero following the 9/11 tragedy were exposed to cement dust, smoke, glass fibers, and heavy metals. Exposure to high levels of such particulate matter caused significant damage to first responders' kidneys, according to research presented at ASN Kidney Week 2013 November 9 at the Georgia World Congress Center in Atlanta, GA.
Gilead Sciences, Inc. announced today its results of operations for the fourth quarter and full year 2012.
› Verified 3 days ago
Dr. Syed Fasahat Hamzavi, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 43151 Dalcoma Dr, Suite 1, Clinton Twp, MI 48038 Phone: 586-286-8720 Fax: 586-286-8723 | |
Meredith Lindsay Price, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 43151 Dalcoma Dr, Clinton Twp, MI 48038 Phone: 586-286-8720 | |
Janine Mangini, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 16520 19 Mile Rd, Clinton Twp, MI 48038 Phone: 586-253-7200 Fax: 586-263-5331 |